Aim. Assess the association of plasma vitamin D levels or vitamin D supplementation in the outcomes of COVID- 19. Methods. PubMed, EMBASE, and Cochrane Library databases were searched. Studies with COVID-19 patients that reported an association between plasma vitamin D levels or vitamin D supplementation and mortality, need of hospitalization, ICU admission, or ventilation requirement published until December 8, 2020, were included. The risk ratio (RR) and confidence interval (CI) were pooled using a fixed-effects model. Results. A total of 16 studies were included in the meta-analysis, eleven cohorts, one case-control, one randomized clinical trial, and two quasi-experimental studies. Low plasma vitamin D levels in patients with COVID-19 were associated with mortality (RR=1.42, 95%CI 1.14 – 1.71), need for ICU admission (RR=1.76, 95%CI 1.03-2.49), and need for ventilation (RR=3.58, 95%CI 1.45-5.70). Regular supplementation showed a decreased risk of death, and vitamin D supplementation in patients with COVID-19 showed a decrease in the need for ICU admission. Conclusion. Sufficient vitamin D level is associated with better outcomes in patients with COVID-19. Vitamin D supplementation in patients with COVID-19 appears to reduce the risk of ICU admission and regular supplementation reduces mortality.